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INTRODUCTION 
 
p53 family is one of the most powerful families of 
genes due to the large spectrum of role that plays from 
tumour suppression, maintenance of the cellular 
homeostasis, contribution to development, reproduction 
and ageing [1-11]. As transcription factors, the three 
members, p53, p63 and p73, sharing high degree of 
structural homology, especially in their DNA-binding 
domains [12], regulate the expression of genes crucial 
for a wide range of cellular processes, including cell 
cycle arrest/apoptosis, senescence, metabolism[13-19], 
autophagy as well as terminal differentiation in specific 
cell types, such as neurons for p73[20-22] and keratinocytes 
for p63[23-27]. The functional and physical interplay 
within the family members is also thought to play 
biological roles and the interaction with the mutated 
forms of p53 can have implications in cancer [28-36].   
 
Similar to 95% of human genes [37, 38] TP73 gene 
generates multiple protein isoforms, which arise as a 
result of alternative promoter (P1 and P2) control and 
differential mRNA splicing at the 3'end. P2 activity 
generates ΔNp73 isoforms that lack the transactivation 
(TA) domain present in the N terminus of the full length 
p73 protein (TAp73); alternative splicing, instead, leads 
to 7 isoforms (α- η) varying in activity and specificity 
[39-41]. 
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ABSTRACT 
 
The p53 family member p73 controls a wide range of cellular function. Deletion of p73 in mice results in 
increased tumorigenesis, infertility, neurological defects and altered immune system. Despite the extensive 
effort directed to define the molecular underlying mechanism of p73 function a clear definition of its 
transcriptional signature and the extent of overlap with the other p53 family members is still missing. Here we 
describe a novel TAp73 target, ATP7A a member of a large family of P-type ATPases implicated in human 
neurogenerative conditions and cancer chemoresistance. Modulation of TAp73 expression influences basal 
expression level of ATP7A in different cellular models and chromatin immunoprecipitation confirmed a physical 
direct binding of TAp73 on ATP7A genomic regions. Bioinformatic analysis of expression profile datasets of 
human lung cancer patients suggests a possible implication of TAp73/ATP7A axis in human cancer. These data 
provide a novel TAp73-dependent target which might have implications in ageing-related diseases such as 
cancer and neurodegeneration.  
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p73 plays critical functions in cellular processes such as 
neuronal development and differentiation [32, 42-48], 
and metabolic control [42, 49-57]. Mimicking p53 
function, TAp73 controls cell cycle arrest and apoptosis 
as well as genome integrity protection in germline and 
somatic cells, impacting fertility and cancer [9, 29, 58-
61]. Differently from TP53 gene, in cancer cells p73 is 
rarely mutated, but shows often dysregulated 
expressions. Isoform-specific knockout mice revealed 
that the two major N-terminal p73 isoforms, TAp73 and 
ΔNp73, play opposite role in cancer [6, 62]. TAp73 
deficiency predisposes to spontaneous cancer and 
increases the susceptibility to carcinogens [62], whereas 
the absence of ΔNp73 decreases tumour growth [63]. 
The impact of p73 deregulation on cancer cell biology 
can indeed depend on the relative expression of TAp73 
and ΔNp73 isoforms [64]. As a result, most studies in 
cancer-related fields focus their attention on the analysis 
of changes in TAp73 and ΔNp73 expression levels. 
ΔNp73 is thought to inhibit the activity of the 
transcriptional competent isoform TAp73, with a fine 
molecular tuning. ΔNp73 can indeed counteract TAp73 
tetramerization or compete for promoter binding. The 
TAp73/ΔNp73 ratio in cells subjected to 
chemotherapeutic agents could therefore be crucial. 
TAp73 contributes to genomic stability of somatic and 
germline cells by controlling the mitotic checkpoints.  
Furthermore, TAp73 interacts with kinetochore proteins 
Bub1 and Bub3 to control the spindle assembly. 
Deregulation of TAp73 in cancer are consequentially 
expected to impact on polyploidy [6]. More recent work 
showed that TAp73 can physically bind and control 
stability of the hypoxia-inducible factor 1α (HIF-1α). In 
hypoxic tumour, expression of TAp73 represses 
activation of HIF-1, thus limiting tumour angiogenesis 
and therefore progression towards advanced stages [60, 
65-67]. Additional contribution of p73 to tumour cell 
biology might be mediated by its support to cellular 
anti-oxidant defence and anabolic processes. This is 
partially mediated by a TAp73-dependent regulation on 
mitochondrial proteins synthesis under oxidative stress 
[14] and by a transcriptional control of metabolic 
enzymes responsible for GSH synthesis, such as 
glutaminase-2 (GLS-2) [50, 52] and glucose-6-
phosphate-dehydrogenase (G6PD) [53]. 
 
However, despite the important effort placed by 
scientific community, we are very far from a dissection 
of p73 transcriptional programme and a clear 
discrimination of this from the transcriptome of the 
siblings p53 and p63. By re-analysing previously 
published high throughput genomic screening approach 
(gene microarrays) and filtering data by using 
bioinformatic tools we aimed to identify novel p73 
transcriptional targets. Our analysis, supported by in 
vitro data and clinical analysis identified a previously 
unknown relationship between TAp73 and ATP7A (or 
MNK), a gene encoding for a transmembrane P-type 
ATPase transporter required for copper homeostasis in 
mammals [68]. ATP7A is recognized as a critical 
copper-transport protein with multiple important 
cellular functions. Mutations is ATP7A are responsible 
for Menkes disease, a X-linked recessive disorder 
characterized by growth retardation, neurodegeneration, 
and peculiar hair [69]. In addition, over-expression of 
ATP7A is observed in multiple cancers, and recent 
studies suggest that this copper efflux transporter play 
an important role in platinum drug resistance [70-76]. 
Our data demonstrate a TAp73-dependent ATP7A 
transcription control and a possible clinical relevance of 
this axis for lung cancer patients. Our finding might 
delineate the possible underlining mechanisms of 
different ageing-related conditions, such as cancer and 
neurodegeneration, where alterations of the 
TAp73/ATP7A axis might play a direct impact.  
 
RESULTS 
 
ATP7A is within the top TAp73 candidate target 
genes 
 
To further deepen TAp73 functions as transcriptional 
factor we firstly started analysing two previously 
reported global gene expression analysis in TAp73 
silenced cells, p53-null human non-small cell lung 
carcinoma cell line H1299 [65] and human embryonic 
kidney cell line 293T [14]. Crossing the two lists and 
considering the top ranked genes, in terms of fold 
change, we selected the ones with established role or 
suspected involvement in tumour biology. Hence, we 
tested the synergist effect of the expression of each 
individual gene (from a list including 175 genes) with 
p73 expression on survival outcome in different cancer 
datasets by a bioinformatic datamining tool we 
previously established, Syntarget [77]. Not surprisingly 
the most represented cancer type was lung cancer: 20 of 
the 21 genes found clinically synergize with TP73 
(p<0.05) in Lung Adenocarcinoma stage I-II 
(GSE31210) and Lung Cancer (GSE30219) datasets. 
Indeed, previous studies have showed that 
TAp73−/− mice spontaneously develop lung carcinomas, 
and altered ratio TAp73/ΔNp73 is frequently reported in 
human lung cancer [62, 78]. Thus, we selected 5 genes 
of these (SPP1, TET2, CABLES1, JPH1 and ATP7A) 
that more significantly synergize with TP73, 
influencing more robustly oncological patients overall 
survival. A representative work flow of the followed 
rationale is shown in Figure 1a.  
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TAp73 silencing influences ATP7A expression level 
 
To explore potential downstream targets of TAp73 we 
analysed the expression level of the top 5 candidate 
genes following overexpression and silencing of TAp73 
by transfection of pcDNA HA-TAp73 α-β and siRNA-
1/2 p73 in both H1299 and 293T cell lines. p73 
silencing in both cell lines resulted in a significant 
ATP7A transcript downregulation (Figure 1c, Figure 
2a). In H1299 overexpression assay only CABLES1, a 
gene encoding for a protein well-known involved in the 
cell cycle regulation [79], showed slight mRNA level 
increase (1.5-2-fold increase) (Figure 1b). This data, 
however, was not confirmed in 293T cells 
overexpressing TAp73 (Supplementary Figure 1c). The 
remaining genes showed similar mRNA level 
fluctuation, however not always high consistency was 
observed in both models (Figure 1b, c and 
Supplementary Figure 1a, b). p73 and p21 expression 
levels were measured by RT-qPCR to verify efficiency 
of TAp73 overexpression and silencing (Figure 2b and 
Supplementary Figure 1c).  
We decided to focus on ATP7A due to the more 
significant and consistent regulation observed. ATP7A 
mRNA reduction in p73 knocked-down cells was 
accompanied by a significant decrease of the protein 
level, more evident in the 293T model (Figure 2c,d). In 
addition, H1299 showed also a moderated, but 
consistent upregulation of ATP7A protein upon TAp73 
overexpression (Figure 2e). 
 
Collectively, these data demonstrate a TAp73-
dependent regulation of ATP7A expression at both 
protein and mRNA level. 
 
TAp73 binds ATP7A genomic regions 
 
The above results suggested a relationship between 
TAp73 and ATP7A transcript. Hence, we asked 
whether a TAp73-dependent transcriptional regulation 
of ATP7A was associated to a direct physical binding of 
TAp73 to ATP7A promoter region. 
 
In addition to the canonical upstream promoter, found 
by using Eukaryotic Promoter Database (labelled 
 
 
Figure 1. Identification of new TAp73 transcriptional targets. (a) Schematic workflow of putative TAp73 transcriptional target 
analysis; most influenced genes in H1299 (Amelio et al.) [65] and 293T (Marini et al.) [14] (shTAp73) were analysed by filtering ones 
more related with tumor biology; searching for previous evidence were done on PubMed (NCBI). Gene expressions effect on 
oncological patients survival and synergical effect with Tp73 on cancer outcome were analysed studying KM curves in all available 
datasets in web based online tool Syntarget. (b) mRNA levels of SPP1, TET2, CABLES1, JPH1, ATP7A were analysed by quantitative PCR 
after HA-TAp73 α and β overexpression. Relative expression of genes was normalized against TBP and calculated as fold change to the 
control treatment (empty vector, EV). Data is reported as mean ± s.d. of three experiments. * p < 0.05 (Student's T-test). (c) mRNA 
levels of genes of interest were analysed by quantitative PCR after siRNA-1 p73 and siRNA-2 p73 treatment. Relative expression of 
genes was normalized against TBP and calculated as fold change to the control treatment (siCTRL, Scr). Data is reported as mean ± 
s.d. of three experiments. *** p < 0.0001, ** p < 0.001, * p < 0.05 (Student's T-test). 
 
www.aging-us.com 3748 AGING 
yellow in Figure 3a), MatInspector Professional 
Software in silico analysis identified 2 regions 
containing responsive elements (REs) for p53-family 
proteins. One of these two (labelled in red in Figure 3a) 
included a 25 nucleotides sequence (ChrX: 77,961,553-
77,962,65 – intron 1/21) with a 0.947 value of matrix 
similarity. Due to lower matrix similarity, we decided 
not to consider the other one, containing potentially 6 
REs, four of them specific for p63 protein. 
 
Immunoprecipitated chromatin with anti-HA antibody 
from HA-TAp73 overexpressing H1299 and 293 T cells 
showed specific binding of TAp73 on the REs identified 
in the promoter region (Eukaryotic Promoter Database) 
and in the intron 1 (MatInspector Professional 
Software) (Figure 3b). MDM2 was tested as positive 
control of TAp73 binding, whereas SAT2 represented a 
negative control.  
 
Overall our data demonstrate a relationship between 
TAp73 and ATP7A. TAp73 directly binds ATP7A 
promoter region and the RE localized in intron 1, 
suggesting a potential direct transcriptional control, and 
depletion of TAp73 impact on the basal expression level 
of ATP7A. However, TAp73 overexpression appears 
not sufficient to strongly promote ATP7A expression 
level. 
 
p73/ATP7A axis in human cancer 
 
In order to better understand the clinical relevance of 
p73-dependent regulation of ATP7A in human cancer, 
 
 
 
Figure 2. TAp73 regulates ATP7A expression level. (a) ATP7A mRNA levels were analysed by quantitative PCR after TAp73 
silencing (siRNA-1/2 p73). Relative mRNA expression was normalized against TBP and calculated as fold change to the control 
treatment (Scr). Data is reported as mean ± s.d. of three experiments. ** p < 0.001, * p < 0.05 (Student's T-test). (b) p73 and p21 
mRNA levels were analysed by quantitative PCR after TAp73 overexpression (HA-TAp73 α-β) and p73 silencing (siRNA-1/2 p73). Up- 
and downregulation of p21, a TAp73 transcriptional target, confirmed p73 transcriptional activity modulation. Relative expression of 
genes was normalized against TBP and calculated as fold change to the control treatments (EV and Scr). Data is reported as mean ± 
s.d. of two experiments. * p < 0.05 (Student's T-test). (c-e) Protein levels of ATP7A, HA-TAp73 or endogenous TAp73 and GAPDH were 
analysed by WB in cell overexpressing or depleted for TAp73. Figure shows a representative replicate of three independent 
experiments. 
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we evaluated by computational webtools the impact of 
the correlation between p73 and ATP7A in different 
publicly available datasets of expression profiling of 
oncologic patients.  
 
Using human lung cancer datasets we assessed the 
impact of the expressions of the individual genes and 
the combination of both on the patient survival. 
Unexpectedly ATP7A high expression positively 
impacted on patient's survival (P value 1.4e-10) (Figure 
4a), whereas high p73 expression had a marginal but 
negative impact (P value 0.0023) (Figure 4b). However 
interestingly the combination of high expression of both 
genes together highly significantly influenced the 
overall survival of lung cancer patients (P value 3.6e-
13) (Figure 4c). 
An important major difference was observed when the 
lung cancer datasets were selected for the different 
histological subtype. ATP7A expression was 
importantly discriminating good and bad prognosis in 
lung adenocarcinoma patients (P value 9.2e-15), but no 
effect was observed in the subset of samples belonging 
to the squamous cell carcinoma histological subtype 
(Figure 4d, e). 
 
Despite a potential unexpected result, this analysis 
indicated a possible implication of p73/ATP7A axis in 
human lung cancer. According to previously observed 
role of ATP7A in chemoresistance, a high expression 
level would have been expected to define a poor 
prognosis cohort, however unexpectedly our result 
indicates that high level of ATP7A positively influences 
 
 
Figure 3. TAp73 physically binds ATP7A genomic areas. (a) Schematic map of the human ATP7A gene. MatInspector 
professional software suggested promoter region containing p53 family members-response elements is indicated in red; the insert 
shows the sequence of the p53 family member-RE chosen, the nearest to the TSS (ChrX: 77,961,553-77,962,65). In yellow ATP7A 
promoter region found on Eukaryotic Promoter Database by selecting a region from -1000 to 100 bp relative to TSS CAGEseq derived 
(ChrX: 77,909,608- 77,910,867) [Human Dec. 2013 (GRCh38/hg38)]. (b) A tagged TAp73 was overexpressed in H1299 and 293T cell 
lines for 24h. The sonicated chromatin was incubated with anti-HA or IgG antibodies. Immunoprecipitated DNA was amplified by PCR 
with ATP7A primers, one (ATP7A1) amplifying Eukaryotic Database suggested promoter, the other (ATP7A2) recognizing the p53-
response element found on MatInspector. ChIP on MDM2 promoter was performed as a positive control, and ChIP on SAT2 promoter 
as a negative control. NC: PCR negative control. Figure shows a representative replicate of two independent experiments. 
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patient's prognosis. In addition, high expression of both 
ATP7A and p73 is defining a subgroup with a 
significant better prognosis compared to the individual 
contribution of ATP7A and p73. This result indicates 
that the activation of p73/ATP7a axis could play a 
tumour suppressor role in a subgroup of lung cancer 
patients.   
 
DISCUSSION 
 
20 years after the discovery of the p53 homologue, p73, 
we still lack a clear definition of its transcriptional 
signature and the extent of overlap with the ones 
controlled by the other p53 family members [80-82]. 
Here we reanalyse previously published transcriptional 
analysis of TAp73 depleted cells, trying to investigate 
potential novel transcriptional targets responsible for 
TAp73 function.  
 
We describe a novel TAp73 target, ATP7A, that in our 
cellular models appears to require TAp73 expression in 
order to maintain its basal expression level. However, 
following TAp73 overexpression despite we observe 
TAp73 accumulation on ATP7A genomic region, no 
strong effects are observed on ATP7a transcript and 
protein level. This result might have multiple 
explanations. For a certain extent this highlights the 
complexity of specific transcriptional networks. TAp73-
dependent ATP7A regulation could indeed not simply 
rely on the direct TAp73 binding on the ATP7A 
 
 
Figure 4. ATP7A expression affect lung cancer patient’s outcome. Overall survival analysis of lung cancer datasets (see 
Material and Methods for full list) relative to (a) Tp73 expression (232546_at probe, mean expression) (n=1926), (b) ATP7A 
expression (205198_s_at probe, mean expression) (n=1145), (c) Tp73 and ATP7A probes mean expression (n=1145). HGU133A probe 
set. Patients splitted by median. P values showed on the top. Overall survival analysis of lung cancer datasets relative to ATP7A 
expression (205198_s_at probe, mean expression) obtained filtering the results with (d) ”Adenocarcinoma” (n=673) and (e) 
“squamous cell carcinoma” histology type (n=271). HGU133A probe set. Patients split by median. P values showed on the top. 
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genomic sites, but require the interplay with additional 
transcriptional factors. Previous studies in zebrafish 
models have showed that SOD1 transcription is affected 
by ATP7A in a copper responsive manner through the 
transcription factor Sp1 [83-85]. Moreover, Sp1 itself 
binds ATP7A promoter in human intestinal epithelial 
cells being fundamental for the HIF2α-mediated 
induction of gene transcription during iron 
deficiency/hypoxia to regulate iron balance [86]. 
Interplay between TAp73 and HIF family proteins [65], 
Sp1 transcription factor [87, 88] or a hierarchical 
genetic regulation mediated by copper could be 
therefore involved in this regulatory mechanism. 
Downstream pathways altered by TAp73 need to be 
elucidated in the specific context of ATP7A regulation 
to fully clarify all the participants of this signalling. An 
alternative explanation of our results could be that 
TAp73 has the capacity of controlling alternative 
transcriptional signatures in a dosage-dependent 
manner. High expression level of TAp73 could be 
responsible for upregulation of pro-apoptotic/cell cycle 
arrest genes in contexts such as genotoxic stress. Basal 
expression level of TAp73 instead might be responsible 
for the control of homeostatic and/or metabolic 
regulators. These two transcriptional programmes might 
be completely distinguished and might be determined 
by the expression level of TAp73. This would represent 
a potential similarity with p53 functions in DNA 
damage response and basal conditions [89-93].  
 
The biological significance of our findings is strictly 
associated to the lack of clarity regarding the 
implications of p73 for human diseases. KO mouse 
models for p73 show a range of defects that include 
tumour suppression, infertility, neurological defects and 
altered immune system [47, 94]. The complexity of p73 
functions is therefore obviously highlighted by the 
phenotype of the genetic mouse models. The control of 
genomic stability is central to all family members, and 
TAp73 deficiency is associated with genomic instability 
that emerged to be important not only in tumorigenesis 
but also in maturation of oocytes. In addition to this, 
more recently a defective ciliogenesis of multiciliated 
epithelia, such as the upper airway tract, further 
expanded the range of defects observed in p73 mouse 
models. However, despite that, a clear connection of 
p73 with human disease never emerged. p73 deficiency 
in mice is also associated to premature ageing.  
 
The altered mitochondrial metabolism is a root cause 
for premature ageing and mitochondrial dysfunction in 
TAp73 KO mice plays a key role in this context [95-
101]. Oxidative damage promotes cellular senescence in 
vitro and ageing in vivo. TAp73-null MEFs and silenced 
cells are sensitive to oxidative damaging agents such as 
hydrogen peroxide (H2O2). On the other hand, TAp73-
null MEFs grow well in low-oxygen conditions or with 
the addition of antioxidants, conditions that dampen 
oxidative damage [54, 102, 103]. These indicates that 
an important part of p73 functions depends on its 
control of cellular metabolism.  
 
ATP7A is a member of a large family of P-type 
ATPases, which are energy-utilizing membrane proteins 
that pumps ions and lipids across cellular membranes 
[104]. ATP7A has a dual homeostatic and biosynthetic 
functions: exporting copper in excess outside the cell, 
and transporting copper to cuproenzymes at the 
secretory pathway [105]. Depending on the copper 
intracellular concentration and the cellular states, 
ATP7A can be shuttled from the endoplasmic reticulum 
to the plasma membrane, facilitating copper extrusion 
from the cell. Mutations in ATP7A leads to Menkes 
Disease, a lethal paediatric multisystemic disorder 
associated to progressive neurodegeneration [106].  
 
The TAp73/ATP7A axis might play a role in different 
biological contexts, with a potential high interest in 
ageing-associated diseases, such as cancer and 
neurodegeneration. Our computational analysis of 
expression profiling datasets of human cancer 
highlighted a potential correlation of TAp73/ATP7A 
with cancer pathogenesis; further studies will determine 
if this is a simple correlative connection, or an actual 
causative relationship. Despite a role in human cancer 
of ATP7A has been identified in drug-resistance (drug 
extrusion from cancer cells), our data indicate that high 
level of ATP7A is a positive prognostic factor, which 
becomes even stronger when concurrent with high 
TAp73 expression. The data are therefore suggestive of 
a potential implication of TAp73/ATP7A axis in tumour 
suppression.  
 
Implication of TAp73 in mouse neurodevelopment and 
deregulation of TAp73 expression in human 
neurodegenerative conditions might be suggestive of 
role of TAp73/ATP7A axis also in neuro-biology. 
Possibly the altered TAp73-dependent regulation of 
ATP7A during ageing could produce neuro-toxic effects 
responsible for progressive neurodegeneration similar to 
the severe manifestations observed in Menkes Disease. 
However, in absence of any experimental evidence 
these speculations might only indicate potential future 
research directions aimed to better define p73 
implications in human diseases.   
 
MATERIALS AND METHODS 
 
Cell Culture 
 
The human non-small cell lung carcinoma cell line 
NCI-H1299 were cultivated in RPMI medium 1640 
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(Gibco, Life Technologies, Carlsbad, CA, USA) 
containing 4.5 g/L D-Glucose, 2.383 g/L HEPES 
Buffer, L-Glutamine, 1.5 g/L Sodium Bicarbonate, and 
110 mg/L Sodium Pyruvate, supplemented with 50 
units/mL Penicillin, 50 mg/mL Streptomycin (Gibco), 
and 10% (vol/vol) FBS (Labtech, Heathfield, UK). The 
human embryonic kidney cell line HEK-293 were 
cultivated in Dulbecco’s Modified Eagle Medium 
(Gibco) containing 4.5 g/L D-Glucose, L-Glutamine, 
and Pyruvate, supplemented with 50 units/ mL 
Penicillin, 50 mg/mL Streptomycin (Gibco), and 10 % 
(v/v) FBS (Labtech). All cell cultures were maintained 
37 °C with 5% CO2 in a humidified incubator. 
 
Cell transfection 
 
For overexpression, H1299 cells were seeded 24 h 
before transfection. Transfection was performed with 
10 μg DNA (pcDNA empty, pcDNA HA-TAp73α, 
pcDNA HA-TAp73β) per 10 cm dish with 
1.2 × 106 cells seeded using Lipofectamine 2000 
Reagent (Invitrogen). Cells were collected 24 h after 
transfection. For 293T cells transfection was performed 
with 3 μg DNA per 10 cm dish with 2.5 × 106 cells 
seeded using Effectene reagent (Qiagen, Manchester, 
UK) and cells collected 24 h after transfection. 
For p73 knockdown in H1299 and 293 T 1.2 × 106 and 
2.5 × 106 cells, respectively, were seeded per 10 cm 
dish 24 h before transfection. Transfection was 
performed using 50 nM siRNA [control siRNA, siRNA-
2 p73-1 and siRNA-2 p73-2 (Ambion)] and 
Lipofectamine RNAiMAX (Invitrogen). Cells were 
collected 48 h after transfection. 
 
RNA extraction and analysis 
 
Total RNA was isolated from cells using the RNEasy 
Mini Kit (Qiagen), according to the Qiagen company 
protocol. 2 μg of total RNA was used to prepare cDNA 
using RevertAid H minus First strand cDNA Synthesis 
kit (ThermoScientific), using Random primers and the 
protocol from the kit. qPCR was performed using 1/10 
of the prepared cDNA and Power SYBR Green PCR 
Master Mix (Applied Biosystems). Relative gene 
expression was analyzed in accordance with 7500 
Software version 2.0.6 of Applied Biosystems. Gene 
expression levels were quantified according to the 
comparative ΔΔCt method and normalized to 
expression of the TBP housekeeping gene. Sequences of 
the primers used for the qPCR are: 
 
TAp73 Fw CAGACAGCACCTACTTCGACCTT, Rev 
CCGCCCACCACCTCATTA;  
p21 Fw CCTGTCACTGTCTTGTACCCT,  Rev 
GCGTTTGGAGTGGTAGAAATCT; 
TBP Fw TCAAACCCAGAATTGTTCTCCTTAT, Rev 
CCTGAATCCCTTTAGAATAGGGTAGA; 
SPP1 Fw GAGGGCTTGGTTGTCAGC, Rev 
CAATTCTCATGGTAGTGAGTTTTCC; 
CABLES1(transcript variant 2) Fw 
TCGCGACAGTACCCAAGTC, Rev 
TCAAACTCACTGCACCAGTTG; 
TET2 Fw AAAGATGAAGGTCCTTTTTATACCC, 
Rev ATAGCTTTACCCTTCTGTCCAAAC; 
JPH1 Fw GACATCGCGAGAGCTGTG, Rev 
TTCCTGAAATCTCTGTTTGACG; 
ATP7A (transcript variant 1) Fw 
TCTTCCAGGATTGTCTGTTATGAA, Rev 
ACCAGCTCCGAAAAACTG;    
ATP7A (transcript variant 2) Fw 
TCTTCCAGGATTGTCTGTTATGAA, Rev 
CCTCTGATGTTTTGCCCTGTA; 
ATP7A (transcript variant 3) Fw 
TGTGCATCACATTAAGGTAAAGGTA, Rev 
AGTTCCCACAATGGCCAAGA. 
 
Western blotting 
 
For protein extraction, cells were lysed in RIPA buffer 
with protease inhibitor cocktail tablets Complete, 
EDTA-free (Roche) and phosphatase inhibitor cocktail 
tablets PhosSTOP (Roche). Lysates were measured for 
protein concentration by using the Bio-Rad Protein 
Assay (Bio-Rad), then mixed with Laemmli loading 
buffer, electrophoresed on SDS-PAGE gels and 
separated proteins transferred to PVDF blotting 
membranes (Amersham, GE Healthcare). Membranes 
were blocked for 1 h in 10% (m/vol) dry milk dissolved 
in TBS with 1% (vol/vol) Tween-20 (TBSt); incubated 
with primary antibodies overnight and with secondary 
antibodies conjugated with horseradish peroxidase, for 
1 h. Antibodies were diluted in 10% dry milk in TBSt: 
anti-HA 1:1000 (Covance), anti-GAPDH 1:40000 
(Sigma), anti-p21, anti-p73 1:3000 (Bethyl), anti-
ATP7A 1:500 (Santa Cruz). To detect the signal ECL 
Western Blotting Detection Reagent (Amersham, GE 
Healthcare) or SuperSignal West Dura 
Chemiluminescent Substrate (Thermo Scientific) was 
used. 
 
Promoter region analysis 
 
Analysis of promoter region was performed using 
MatInspector Professional software by Genomatix 
(https://www.genomatix.de) and the Eukariotic 
Promoter Database (https://epd.vital-it.ch/index.php). 
 
Chromatin Immunoprecipitation assay 
 
TAp73α was overexpressed for 24 h in H1299 and 293T 
cell lines (see cell transfection section for details). Cells 
were collected fixed in 37% formaldehyde and 
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subjected to sonication for DNA shearing. Chromatin 
was sonicated (around 500 bp) and immunoprecipitated 
with/without 10 μL anti-HA antibodies (Covance) or 
10 μL nonspecific immunoglobulin G (IgG) antibodies 
(Invitrogen) using the MAGnify ChIP System kit 
(Invitrogen). The co-immunoprecipitated DNA 
fragments were amplified by PCR. MDM2 was used as 
positive control. SAT2 was used as negative control. 
 
ATP7A (1) Fw GGTTTCGCTTTTGTCGTGGG, Rev 
TGAAAAGGAACGCGTGGTCT; 
ATP7A (2) Fw ATACCCTTGTACTGCTTCCCAC, 
Rev TAGGATGAGTTCAGGTGGCG; 
MDM2 Fw GGTTGACTCAGCTTTTCCTCTTG, Rev 
GGAAAATGCATGGTTTAAATAGCC;  
SAT2 Fw CTGCAATCATCCAATGGTCG, Rev 
GATTCCATTCGGGTCCATTC. 
 
Bioinformatic analyses 
 
First bioinformatic analysis, to test gene synergy in 
cancer, was performed using Syntarget by 
ChemoProfiling (http://www.chemoprofiling.org). All 
available datasets had been checked. Survival analysis 
on lung cancer patients was performed by Kaplan-Meier 
Plotter (http://kmplot.com/analysis/). Datasets 
considered were: CAARRAY, GSE14814, GSE19188, 
GSE29013, GSE30219, GSE31210, GSE3141, 
GSE31908, GSE37745, GSE43580, GSE4573, 
GSE50081, GSE8894, TGCA. 
 
Statistics 
 
Technical as well as biological triplicates of each 
experiment were performed. Error bars indicate ±S.D. 
in each figure. Statistical significance was determined 
using the unpaired two-tailed Student's t-test using 
GraphPad Software. A p-value ≤0.05 was considered 
statistically significant. 
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SUPPLEMENTARY MATERIAL 
 
 
 
 
Supplementary Figure 1. TAp73 overexpression and silencing in 293T cells and H1299. (a) mRNA levels of SPP1, TET2, 
CABLES1, JPH1, ATP7A were analysed by quantitative PCR after HA-Tap73 α and β induction. Relative expression of genes was 
normalized against TBP and calculated as fold change to the control treatment (empty vector, EV). Data is reported as mean ± s.d. of 
two experiments. * p < 0.05 (Student's T-test). (b, c) mRNA levels of genes of interest were analysed by quantitative PCR after siRNA-
1 p73 and siRNA-2 p73 treatment. Relative expression of genes was normalized against TBP and calculated as fold change to the 
control treatment (siCTRL, Scr) Data is reported as mean ± s.d. of two experiments. * p < 0.05 (Student's T-test). (c) p73 and p21 
mRNA levels were analysed by quantitative PCR after TAp73 overexpression (HA-Tap73 α-β) and p73 silencing (siRNA-1/2 p73). Up- 
and downregulation of p21, a TAp73 transcriptional target, confirmed p73 transcriptional activity modulation. Relative expression of 
genes was normalized against TBP and calculated as fold change to the control treatments (EV and Scr). Data is reported as mean ± 
s.d. of three experiments. *** p < 0.0001, ** p < 0.001, * p < 0.05 (Student's T-test). 
 
